ATXI Stock Price | Avenue Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Avenue Therapeutics Inc • ATXI

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Avenue Therapeutics Inc

Ticker

ATXI

Trading on

PINK

ISIN

US05360L3042

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Alexandra MacLean M.D.

Headquarters

1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154

Employees

Website

avenuetx.com

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Metrics

BasicAdvanced

Market cap

$0.8M

P/E ratio

EPS

-$15.79

Dividend Yield

0.00%

Beta

0.1

Forward P/E ratio

17.99

EBIDTA

Ex dividend date

Price & volume

Market cap

$0.8M

Average daily volume

0.1M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

17.99

PEG ratio

Trailing P/E

Price to sales

Price to book

0.29

Earnings

EPS

-$15.79

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

0.1

52-week High

$10.43

52-week Low

$0.25

50-day moving average

$1.19

200-day moving average

$2.19

Short ratio

0.65

Short %

2.91%

Management effectiveness

ROE (TTM)

931.95%

ROA (TTM)

311.89%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

67.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

3.1M

Float

2.8M

Insiders %

16.39%

Institutions %

9.30%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$8.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$15.40

-$9.00

71.11%

Q1 • 24Beat

-$6.43

-$1.05

512.38%

Q2 • 24Beat

-$1.92

-$0.94

104.26%

Q3 • 24Beat

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-3.1M

∞%

Q3 • 24

$0M

$-1.5M

∞%

Q4 • 24

NaN%

49.80%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$2.6M

$1M

37.07%

Q3 • 24

$2.7M

$0.8M

30.54%

Q4 • 24

1.79%

16.14%

17.61%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-2.9M

$0M

$0.6M

$-2.9M

Q3 • 24

$-0.8M

$0M

$0.8M

$-0.8M

Q4 • 24

73.55%

34.22%

73.55%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Avenue Therapeutics Inc share?

Avenue Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Avenue Therapeutics Inc have?

Avenue Therapeutics Inc currently has 3.1M shares.

Does Avenue Therapeutics Inc pay dividends?

No, Avenue Therapeutics Inc doesn't pay dividends.

What is Avenue Therapeutics Inc 52 week high?

Avenue Therapeutics Inc 52 week high is $10.43.

What is Avenue Therapeutics Inc 52 week low?

Avenue Therapeutics Inc 52 week low is $0.25.

What is the 200-day moving average of Avenue Therapeutics Inc?

Avenue Therapeutics Inc 200-day moving average is $2.19.

Who is Avenue Therapeutics Inc CEO?

The CEO of Avenue Therapeutics Inc is Dr. Alexandra MacLean M.D..

How many employees Avenue Therapeutics Inc has?

Avenue Therapeutics Inc has 2 employees.

What is the market cap of Avenue Therapeutics Inc?

The market cap of Avenue Therapeutics Inc is $0.8M.

What is the P/E of Avenue Therapeutics Inc?

The current P/E of Avenue Therapeutics Inc is null.

What is the EPS of Avenue Therapeutics Inc?

The EPS of Avenue Therapeutics Inc is -$15.79.

What is the PEG Ratio of Avenue Therapeutics Inc?

The PEG Ratio of Avenue Therapeutics Inc is 0.

What do analysts say about Avenue Therapeutics Inc?

According to the analysts Avenue Therapeutics Inc is considered a buy.